EA201891304A1 - ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ - Google Patents

ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ

Info

Publication number
EA201891304A1
EA201891304A1 EA201891304A EA201891304A EA201891304A1 EA 201891304 A1 EA201891304 A1 EA 201891304A1 EA 201891304 A EA201891304 A EA 201891304A EA 201891304 A EA201891304 A EA 201891304A EA 201891304 A1 EA201891304 A1 EA 201891304A1
Authority
EA
Eurasian Patent Office
Prior art keywords
mtap
null
mat2a
treatment
malignant tumors
Prior art date
Application number
EA201891304A
Other languages
English (en)
Inventor
Катя Марьон
Сун Еунь Чо
Original Assignee
Агиос Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Агиос Фармасьютикалс, Инк. filed Critical Агиос Фармасьютикалс, Инк.
Publication of EA201891304A1 publication Critical patent/EA201891304A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A61K31/025—Halogenated hydrocarbons carbocyclic
    • A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

Согласно настоящему изобретению предусмотрены диагностические и прогностические способы прогнозирования эффективности лечения пациента со злокачественной опухолью с помощью ингибитора MAT2A. Предусмотрены способы прогнозирования чувствительности роста опухолевых клеток к ингибированию с помощью ингибитора MAT2A, предусматривающие оценку того, отсутствует ли в опухолевой клетке ген MTAP, на основании чего клетки, которые являются MTAP-null, являются чувствительными к ингибированию с помощью ингибиторов MAT2A.
EA201891304A 2015-12-03 2016-12-02 ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ EA201891304A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562262750P 2015-12-03 2015-12-03
US201662297572P 2016-02-19 2016-02-19
PCT/US2016/064619 WO2017096165A1 (en) 2015-12-03 2016-12-02 Mat2a inhibitors for treating mtap null cancer

Publications (1)

Publication Number Publication Date
EA201891304A1 true EA201891304A1 (ru) 2019-01-31

Family

ID=57614465

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891304A EA201891304A1 (ru) 2015-12-03 2016-12-02 ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ

Country Status (12)

Country Link
US (1) US20180371551A1 (ru)
EP (1) EP3383375A1 (ru)
JP (2) JP6877429B2 (ru)
KR (1) KR20180100125A (ru)
CN (1) CN108601752A (ru)
AU (1) AU2016364855B2 (ru)
CA (1) CA3006743A1 (ru)
EA (1) EA201891304A1 (ru)
IL (1) IL259773A (ru)
MX (1) MX2018006781A (ru)
SG (1) SG11201804360XA (ru)
WO (1) WO2017096165A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107964042B (zh) 2012-05-30 2022-04-19 中外制药株式会社 靶组织特异性抗原结合分子
KR102284503B1 (ko) 2013-12-04 2021-07-30 추가이 세이야쿠 가부시키가이샤 화합물의 농도에 따라 항원 결합능이 변화되는 항원 결합 분자 및 그의 라이브러리
US11376256B2 (en) 2018-07-19 2022-07-05 Agency For Science, Technology And Research Method of treating a methionine-dependent cancer
WO2020123395A1 (en) 2018-12-10 2020-06-18 Ideaya Biosciences, Inc. 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors
CN113613676A (zh) * 2019-03-19 2021-11-05 中外制药株式会社 包含对抗原的结合活性因mta而变化的抗原结合结构域的抗原结合分子及用于获得该抗原结合结构域的文库
WO2021023609A1 (en) * 2019-08-02 2021-02-11 Glaxosmithkline Intellectual Property Development Limited Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor
WO2021158792A1 (en) * 2020-02-04 2021-08-12 Agios Pharmaceuticals, Inc. Methods of treating autoimmune or inflammatory diseases or disorders
CN113999232A (zh) * 2020-07-28 2022-02-01 南京正大天晴制药有限公司 Mat2a抑制剂
TW202227082A (zh) * 2020-08-12 2022-07-16 美商施維雅製藥有限公司 用於治療癌症之組合療法
KR20240019172A (ko) * 2021-06-02 2024-02-14 아이디어야 바이오사이언시스 인코포레이티드 Mat2a 억제제 및 유형 ii prmt 억제제를 포함하는 병용 요법
CN113476450B (zh) * 2021-08-10 2023-04-28 江南大学 Epz015666在制备用于防治血管内膜增生类疾病的药物中的应用
CN114028572B (zh) * 2021-11-30 2022-11-25 清华大学 Mat2a抑制剂用于治疗哮喘的新应用
WO2024080788A1 (ko) 2022-10-13 2024-04-18 한미약품 주식회사 신규한 트리사이클 유도체 화합물 및 이의 용도
CN115825214A (zh) * 2022-11-30 2023-03-21 厦门大学 一种基于MALDI-TOF-MS体外筛选hMAT2A蛋白抑制剂的方法及其应用

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503035B1 (en) 1978-11-24 1996-03-19 Hoffmann La Roche Protein purification process and product
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US5231176A (en) 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
US4868103A (en) 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
US4843155A (en) 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
DE69326967T2 (de) 1992-01-17 2000-06-15 Lakowicz Joseph R Phasenmodulationsenergieübertragungsfluoroimmunassay
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5942393A (en) 1993-12-29 1999-08-24 The Regents Of The University Of California Method for the detection of the presence or absence of methylthioadenosine phosphorylase (MTASE) in a cell sample by detection of the presence or absence of MTASE encoding nucleic acid in the cell sample
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
US5861510A (en) 1995-04-20 1999-01-19 Pfizer Inc Arylsulfonyl hydroxamic acid derivatives as MMP and TNF inhibitors
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
CN1202932A (zh) 1995-10-23 1998-12-23 儿童医学中心公司 治疗用抗血管生成的组合物和方法
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
WO1997032856A1 (en) 1996-03-05 1997-09-12 Zeneca Limited 4-anilinoquinazoline derivatives
BR9709974A (pt) 1996-06-27 1999-08-10 Pfizer Derivados de 2-(2-oxo-etidileno)-imidazolidin-4-ona e seu uso como inibidores da transferase da proteina de farnesila
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
ID19430A (id) 1996-07-13 1998-07-09 Glaxo Group Ltd Senyawa senyawa heterosiklik
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
TR199900066T2 (xx) 1996-07-18 1999-04-21 Pfizer Inc. Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
CA2264284A1 (en) 1996-08-23 1998-02-26 Ralph P. Robinson Arylsulfonylamino hydroxamic acid derivatives
PT950059E (pt) 1997-01-06 2004-10-29 Pfizer Derivados de sulfona ciclicos
PT977733E (pt) 1997-02-03 2003-12-31 Pfizer Prod Inc Derivados de acido arilsulfonilamino-hidroxamico
CA2279863A1 (en) 1997-02-07 1998-08-13 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
AU722784B2 (en) 1997-02-11 2000-08-10 Pfizer Inc. Arylsulfonyl hydroxamic acid derivatives
EP0984930B1 (en) 1997-05-07 2005-04-06 Sugen, Inc. 2-indolinone derivatives as modulators of protein kinase activity
CA2291709A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
IL134300A (en) 1997-08-08 2004-07-25 Pfizer Prod Inc Derivatives of aryloxyacrylylsulfonaminoaminoxamic acid derivatives, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of arthritis, cancer and other diseases characterized by the activity of metalloproteinase-13 of matrix
JP4959049B2 (ja) 1997-08-22 2012-06-20 アストラゼネカ・ユーケイ・リミテッド 血管新生阻害剤としてのオキシインドリルキナゾリン誘導体
CA2303830A1 (en) 1997-09-26 1999-04-08 Merck & Co., Inc. Novel angiogenesis inhibitors
CZ20001709A3 (cs) 1997-11-11 2001-12-12 Pfizer Products Inc. Deriváty thienopyrimidu a thienopyridinu, farmaceutické kompozice a způsoby léčení na jejich bázi
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
JPH11236333A (ja) 1997-12-30 1999-08-31 Pfizer Prod Inc 抗ガン剤として有用なイミダゾリン−４−オン誘導体
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
EP1080113A4 (en) 1998-05-15 2002-04-17 Imclone Systems Inc TREATMENT OF HUMAN TUMORS USING RADIATION AND GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITORS
CA2314156C (en) 1998-05-29 2010-05-25 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
UA60365C2 (ru) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Производные изотиазола, способ их получения, фармацевтическая композиция и способ лечения гиперпролиферативного заболевания у млекопитающего
US6576420B1 (en) 1998-06-23 2003-06-10 Regents Of The University Of California Method for early diagnosis of, and determination of prognosis in, cancer
US6566131B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of Smad6 expression
EP1107962B1 (en) 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
EE200100118A (et) 1998-08-27 2002-06-17 Pfizer Products Inc. Vähivastaste vahenditena kasulikud alkünüül-asendatud kinoliin-2-ooni derivaadid
US6410323B1 (en) 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
PT1004578E (pt) 1998-11-05 2004-06-30 Pfizer Prod Inc Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
EP1006113A1 (en) 1998-12-02 2000-06-07 Pfizer Products Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth
US6107091A (en) 1998-12-03 2000-08-22 Isis Pharmaceuticals Inc. Antisense inhibition of G-alpha-16 expression
US5981732A (en) 1998-12-04 1999-11-09 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-13 expression
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
ID29584A (id) 1999-02-11 2001-09-06 Pfizer Prod Inc Turunan-turunan kuinolin-2-on tersubstitusi heteroaril yang bermanfaat sebagai zat-zat anti kanker
US6586447B1 (en) 1999-04-01 2003-07-01 Pfizer Inc 3,3-disubstituted-oxindole derivatives useful as anticancer agents
US6046321A (en) 1999-04-09 2000-04-04 Isis Pharmaceuticals Inc. Antisense modulation of G-alpha-i1 expression
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
UA75055C2 (ru) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Производные бензоимидазола, которые применяются как антипролиферативное средство, фармацевтическая композиция на их основании
DE60008206T2 (de) 1999-11-30 2004-12-02 Pfizer Products Inc., Groton Chinolinderivate verwendbar zur Hemmung der Farnesyl-Protein Transferase
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2403397A1 (en) 2000-03-16 2001-09-20 Genetica, Inc. Methods and compositions for rna interference
US6365354B1 (en) 2000-07-31 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of lysophospholipase I expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
WO2004065542A2 (en) 2002-12-30 2004-08-05 Exelixis, Inc. MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
US9044432B2 (en) 2009-12-22 2015-06-02 Ohio State Innovation Foundation Compositions and methods for cancer detection and treatment
CN103764604B (zh) * 2011-01-28 2017-02-08 肯塔基大学研究基金会 茋类似物和治疗癌症的方法
US8940726B2 (en) 2012-12-21 2015-01-27 Epizyme, Inc. PRMT5 inhibitors and uses thereof
EP2935240A1 (en) 2012-12-21 2015-10-28 Epizyme, Inc. Prmt5 inhibitors and uses thereof
US9611257B2 (en) 2012-12-21 2017-04-04 Epizyme, Inc. PRMT5 inhibitors and uses thereof
CA2894157A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. Prmt5 inhibitors and uses thereof
EP2975938A4 (en) 2013-03-15 2017-02-15 Ohio State Innovation Foundation Inhibitors of prmt5 and methods of their use
TWI533873B (zh) 2014-02-12 2016-05-21 中央研究院 治療肝臟疾病之醫藥組成物
CN105039342B (zh) 2015-08-06 2017-12-01 李家平 能抑制MAT2A基因表达的siRNA及其应用

Also Published As

Publication number Publication date
AU2016364855B2 (en) 2019-08-29
AU2016364855A1 (en) 2018-07-05
JP2021098736A (ja) 2021-07-01
MX2018006781A (es) 2018-11-09
CN108601752A (zh) 2018-09-28
EP3383375A1 (en) 2018-10-10
KR20180100125A (ko) 2018-09-07
SG11201804360XA (en) 2018-06-28
IL259773A (en) 2018-07-31
JP2018537473A (ja) 2018-12-20
WO2017096165A1 (en) 2017-06-08
US20180371551A1 (en) 2018-12-27
CA3006743A1 (en) 2017-06-08
JP6877429B2 (ja) 2021-05-26

Similar Documents

Publication Publication Date Title
EA201891304A1 (ru) ИНГИБИТОРЫ MAT2A ДЛЯ ЛЕЧЕНИЯ MTAP-null ЗЛОКАЧЕСТВЕННЫХ ОПУХОЛЕЙ
MX2018008169A (es) Tratamiento de tumores que incorpora isocitrato deshidrogenasa mutante.
MX2022006075A (es) Antagonistas de union a pd-l1 y usos de los mismos para el tratamiento de cancer.
EA201890113A1 (ru) Композиции и способы ингибирования активности аргиназы
MX2023002251A (es) Antagonistas de union al eje pd-l1 y usos de los mismos para el tratamiento de cancer.
EA201591069A1 (ru) Лечение злокачественной опухоли гетероциклическими ингибиторами глутаминазы
MX2017005751A (es) Métodos y biomarcadores para predecir la eficacia y evaluación de un tratamiento con agonista de ox40.
EA201792679A1 (ru) Способы диагностики и лечения злокачественной опухоли
EA201890512A1 (ru) Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
GB2552267A (en) Detection and treatment of disease exhibiting disease cell heterogeneity and systems and methods for communicating test results
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
EA201500835A1 (ru) Терапевтическая и диагностическая мишень для рака, включающая dll3-связывающие реагенты
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
MX368513B (es) Métodos in vitro para el pronóstico, diagnóstico y diseño de una terapia de metástasis de cáncer de pulmón.
MX365421B (es) Método in-vitro para diagnóstico, pronóstico y tratamiento de metástasis de cáncer de próstata usando c-maf.
EA201400117A1 (ru) Способы и нуклеиновые кислоты для определения прогноза у больных раком
EA201300171A1 (ru) Способы и композиции для терапии рака печени
EA201490230A1 (ru) Применение меченых ингибиторов hsp90
TR201907389T4 (tr) Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem.
MX2016007066A (es) Identificacion de marcadores biologicos predictivos asociados con inhibidores de la via de wnt.
MX2015015605A (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
CA2864161A1 (en) Inhibition of the glycine cleavage system for treatment of cancer
WO2018183817A3 (en) Tumor burden as measured by cell free dna
TR201909951T4 (tr) Kanser olduğundan şüphelenilen bir hastanın aflibersept ile tedavisinin sonucunun öngörülmesine yönelik yöntem.